THERAPEUTIC TRIALS IN IDIOPATHIC INFLAMMATORY MYOPATHIES

严重的特发性炎症性肌病(多发性肌炎， 皮肌炎和相关疾病)对 皮质类固醇很难治疗。我们已经承担了三项任务 治疗此类患者的治疗试验：a)对照试验 阶段分离和白细胞分离的双盲试验；b)对照试验， 甲氨蝶呤静脉滴注与亚叶酸钙联合应用的交叉试验 甲氨蝶呤和硫唑嘌呤的联合应用；c)静脉注射的开放试验。 环磷酰胺(已完成)。 在39名患者接受了治疗后，分离试验刚刚结束 完成了。对结果的分析正在进行中。静脉注射的审判。 甲氨蝶呤和联合治疗仍在继续，尽管患有 包涵体肌炎不再进入，因为贫穷 结果在前12例患者中随机分组。

Severe idiopathic inflammatory myopathies (polymyositis, dermatomyositis, and related diseases) that respond poorly to corticosteroids are difficult to treat. We have undertaken three therapeutic trials for the treatment of such patients: a) a controlled double-blind trial of phasmapheresis and leukapheresis; b) a controlled, crossover trial of intravenous methotrexate with leucovorin rescue and combination of methotrexate and azathioprine; c) an open trial of i.v. cyclophosphamide (completed). The trial of apheresis has just been closed after 39 patients have completed it. Analysis of the results is underway. The trial of i.v. methotrexate and combination therapy continues, although patients with inclusion body myositis are no longer being entered because of poor results in the first 12 patients randomized.